睿智医药10月23日获融资买入795.55万元，融资余额1.91亿元

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical experienced a decline in stock price and significant changes in financing activities on October 23, with a net financing outflow of 457.09 million yuan [1] - As of October 23, the total financing and securities balance for Ruizhi Pharmaceutical was 1.91 billion yuan, which represents 3.39% of its circulating market value, indicating a high level of financing [1] - The company reported a financing buy-in of 7.96 million yuan and a financing repayment of 12.53 million yuan on the same day, reflecting a negative net financing activity [1] Group 2 - As of October 20, the number of shareholders for Ruizhi Pharmaceutical was 42,500, a slight decrease of 0.10%, while the average circulating shares per person increased by 0.10% to 11,161 shares [2] - For the first half of 2025, Ruizhi Pharmaceutical achieved an operating income of 534 million yuan, representing a year-on-year growth of 14.75%, and a net profit attributable to the parent company of 25.38 million yuan, which is a significant increase of 140.35% year-on-year [2] - Since its A-share listing, Ruizhi Pharmaceutical has distributed a total of 180 million yuan in dividends, with no dividends paid in the last three years [3]